Thermopylae Holdings Ltd., a 10% owner of AbCellera Biologics Inc. (NASDAQ:ABCL), filed a Form 4 on November 12, 2026, disclosing the purchase of 60,565 common shares at a weighted-average price of $11.54 per share on that same date.

Key Highlights

  • Shares acquired: Thermopylae Holdings Ltd. purchased 60,565 common shares of AbCellera Biologics Inc. on November 12, 2026.
  • Weighted-average price: The reported price of $11.54 per share is a weighted average; individual transaction prices ranged from $11.29 to $11.86, according to the filing.
  • Transaction code: The filing records a "P" (open-market purchase) code for the transaction.
  • Resulting ownership: Following the transaction, Thermopylae Holdings Ltd. directly beneficially owns 56,194,662 common shares.
  • Relationship to issuer: Thermopylae Holdings Ltd. is identified in the filing as a director and 10% owner of AbCellera Biologics Inc.
  • Signing authority: The form was signed by Tryn Stimart as attorney-in-fact on November 12, 2026.

Thermopylae Holdings Ltd. Adds to AbCellera Position in November 2026 Open-Market Purchase

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Thermopylae Holdings Ltd., whose address is listed care of AbCellera Biologics Inc. at 150 W 4th Avenue, Vancouver, British Columbia, Canada, acquired 60,565 common shares of AbCellera Biologics Inc. on November 12, 2026. The filing identifies Thermopylae Holdings Ltd. as both a director and a 10% owner of the issuer.

The filing discloses that the $11.54 price reported is a weighted-average figure. The shares were acquired in multiple transactions at prices ranging from $11.29 to $11.86. The filing states that Thermopylae Holdings Ltd. "undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote."

Following the reported purchase, the filing shows Thermopylae Holdings Ltd. directly beneficially owns 56,194,662 common shares of AbCellera Biologics Inc. No derivative securities transactions were reported in Table II of the filing. The form was filed by one reporting person and was signed by Tryn Stimart as attorney-in-fact on November 12, 2026.

What Was Disclosed

Thermopylae Holdings Ltd. reported an open-market purchase of 60,565 AbCellera Biologics common shares on November 12, 2026, at a weighted-average price of $11.29 to $11.86 per share, bringing its direct beneficial ownership to 56,194,662 shares.